Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of elexacaftor/tezacaftor/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: real-world evidence from the German CF Registry.
Sutharsan S, Dillenhoefer S, Welsner M, Stehling F, Brinkmann F, Burkhart M, Ellemunter H, Dittrich AM, Smaczny C, Eickmeier O, Kappler M, Schwarz C, Sieber S, Naehrig S, Naehrlich L; German CF Registry of the Mukoviszidose e.V. and participating CF sites. Sutharsan S, et al. Among authors: naehrig s. Lancet Reg Health Eur. 2023 Jul 28;32:100690. doi: 10.1016/j.lanepe.2023.100690. eCollection 2023 Sep. Lancet Reg Health Eur. 2023. PMID: 37554663 Free PMC article.
An 8 week open-label interventional multicenter study to explore the lung clearance index as endpoint for clinical trials in cystic fibrosis patients ≥8 years of age, chronically infected with Pseudomonas aeruginosa.
Sutharsan S, Naehrig S, Mellies U, Sieder C, Ziegler J. Sutharsan S, et al. Among authors: naehrig s. BMC Pulm Med. 2020 Jun 12;20(1):167. doi: 10.1186/s12890-020-01201-y. BMC Pulm Med. 2020. PMID: 32532226 Free PMC article. Clinical Trial.
Cystic Fibrosis.
Naehrig S, Chao CM, Naehrlich L. Naehrig S, et al. Dtsch Arztebl Int. 2017 Aug 21;114(33-34):564-574. doi: 10.3238/arztebl.2017.0564. Dtsch Arztebl Int. 2017. PMID: 28855057 Free PMC article. Review.
Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.
Sutharsan S, McKone EF, Downey DG, Duckers J, MacGregor G, Tullis E, Van Braeckel E, Wainwright CE, Watson D, Ahluwalia N, Bruinsma BG, Harris C, Lam AP, Lou Y, Moskowitz SM, Tian S, Yuan J, Waltz D, Mall MA; VX18-445-109 study group. Sutharsan S, et al. Lancet Respir Med. 2022 Mar;10(3):267-277. doi: 10.1016/S2213-2600(21)00454-9. Epub 2021 Dec 20. Lancet Respir Med. 2022. PMID: 34942085 Clinical Trial.
Multi-layer ventilation inhomogeneity in cystic fibrosis.
Krueger-Ziolek S, Schullcke B, Zhao Z, Gong B, Naehrig S, Müller-Lisse U, Moeller K. Krueger-Ziolek S, et al. Among authors: naehrig s. Respir Physiol Neurobiol. 2016 Nov;233:25-32. doi: 10.1016/j.resp.2016.07.010. Epub 2016 Jul 28. Respir Physiol Neurobiol. 2016. PMID: 27476932